Glaxosmithkline (GSK)

 

GSK Share PerformanceMore

52 week high1,724.5 22/06/17
52 week low1,236.5 06/02/18
52 week change -118.0 (-7.29%)
4 week volume189,332,879 01/05/18
price1,500.0
price date1527270316
close1,494.0

Latest NewsMore

GlaxoSmithKline joint venture's HIV treatment approved in Europe

GlaxoSmithKline said a HIV treatment developed by its ViiV Healthcare joint venture with Pfizer and Shionogi had been ...

ViiV granted EU marketing authorisation for Juluca

RNS Number: 7216O GlaxoSmithKline PLC 21 May 2018 Issued: 21 may 2018, London UK - LSE Announcement ViiV Healthcare receives EU marketing authorisation for Juluca (dolutegravir/rilpivirine), the first 2-drug regimen, once-daily, single-pill for the treatment of HIV Juluca maintains viral suppression with two drugs in the smallest single pill regimen Londo...

Director/PDMR Shareholding

RNS Number: 1568O GlaxoSmithKline PLC 15 May 2018 GlaxoSmithKline plc (the ' Company ') Transaction notification 1. Details of PDMR/person closely associated with them ('PCA') a) Name Mr P Thomson b) Position/status President, Global Affairs c) Initial notification/ amendment Initial notification 2. Details of the issuer, emission allowance market participant, ...

Director/PDMR Shareholding

RNS Number: 8651N GlaxoSmithKline PLC 11 May 2018 GlaxoSmithKline plc (the ' Company ') Transaction notification 1. Details of PDMR/person closely associated with them ('PCA') a) Name Ms E Walmsley b) Position/status Chief Executive Officer c) Initial notification/ amendment Initial notification 2. Details of the issuer, emission allowance market participant, a...

Block listing Interim Review

RNS Number: 7281N GlaxoSmithKline PLC 10 May 2018 BLOCK LISTING SIX MONTHLY RETURN Information provided on this form must be typed or printed electronically and provided to an ris . Date: 10 May 2018 Name of applicant: GlaxoSmithKline plc Name of scheme: GlaxoSmithKline plc 2009 Deferred Annual Bonus Plan Period of return: From: 1 Nove...

Director/PDMR Shareholding - replacement

RNS Number: 5703N GlaxoSmithKline PLC 09 May 2018 GlaxoSmithKline plc (the ' Company ') Transaction notification The following amendments have been made to the 'Director/PDMR Shareholding' announcement released on 26 April 2018 at 15:30 under RNS No 2887M. Dr Jesse Goodman acquired 411.275 notional American Depositary Shares ('ADSs') and not 62...

Directorate Change

RNS Number: 5226N GlaxoSmithKline PLC 09 May 2018 Issued: Wednesday 9 May 2018, LSE Simon Dingemans, Chief Financial Officer, to retire from GSK GlaxoSmithKline plc (LSE/NYSE: GSK) today announces that Simon Dingemans, Chief Financial Officer (CFO), GSK, has informed the Board of his intention to retire from the Company and to step down fro...

Most popular FTSE 100, AIM and overseas shares in April 2018

In one of the best months for equity markets in the past decade, Lee Wild reveals which blue chip, AIM and international ...

Fundamental DataMore

P/E ratio79.787
EPS18.8
Dividend yield5.333 %

Latest discussion posts More

  • May Look at Merger Options for Indian Unit

    - GlaxoSmithKline is considering a merger or share swap for its Indian consumer products division, in order to avoid a potential 40% tax burden on the sale of its Horlicks ...
    24-May-2018
    IOMINVESTCOM
  • HIV treatment approval

    GlaxoSmithKline said a HIV treatment developed by its ViiV Healthcare joint venture with Pfizer and Shionogi had been granted marketing approval by the European Commission. The ...
    21-May-2018
    Proverbs 26 vs 5
  • Telegraph - Whistleblower

    Lawsuit alleging dismissal of a whistleblower, not good publicity but doesn't sound like a major issue, given that he "left the company following a reorganisation that resulted ...
    19-May-2018
    Hydrogen Economy

Users' HoldingsMore

Users who hold Glaxosmithkline also hold..
BP50%
STAND.CHART.37%
SAINSBURY(J)25%
3I INF. ORD25%
TESCO25%

Codes & Symbols

ISINGB0009252882
SymbolsGSK, LSE:GSK, GSK.L, GSK:LN, LON:GSK, XLON:GSK